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Background: Lung transplantation is a life-saving option for systemic sclerosis (SSc)-associated
pulmonary arterial hypertension (PAH) and interstitial lung disease (SSc-ILD) patients. Howev-
er, some programs may be concerned about the possibility of excess post-transplantation mor-
tality related to the extra-pulmonary manifestations of SSc. The objective of this study was to
evaluate survival of SSc patients post-lung transplantation. We secondarily evaluated SSc lung
transplant recipient characteristics (age, sex, and type of SSc lung disease), and discussed
post-lung transplantation survival of SSc patients and non-SSc patients (idiopathic PAH, and
ILD).
Methods: A systematic review of MEDLINE, EMBASE, Cochrane Central Registry of Controlled
Trials and CINAHL (all inception to 2012) was performed to identify studies evaluating post-
lung transplant survival in SSc compared to PAH and ILD patients. Two reviewers independently
abstracted study and survival data.
Results: Two hundred twenty-six citations were screened to identify 7 observational studies
reporting SSc patients who underwent single lung, double lung, or heart-lung transplantation.
Mean age at transplantation ranged 46e53 years. SSc post-transplantation survival ranged 69%Rheumatology, Ground Floor, East Wing, Toronto Western Hospital, 399 Bathurst Street, Toronto,
6 603 6417; fax: þ1 416 603 4348.
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2082 I.Y. Khan et al.e91% at 30-days, 69%e85% at 6-months, 59%e93% at 1-year, 49%e80% at 2-years, and 46%e79%
at 3-years. Causes of death included graft failure, infection, cardiac events, hemorrhagic
stroke, respiratory failure, malignancy, pulmonary hypertension, complications of bronchiolitis
obliterans syndrome, anesthetic complication, and scleroderma renal crisis. There were no re-
ports of recurrence of SSc in the lung allograft.
Conclusion: The short-term and intermediate-term survival post-lung transplantation are
similar to IPAH and ILD patients requiring lung transplantation.
ª 2013 Elsevier Ltd. All rights reserved.Introduction
Systemic sclerosis (SSc, scleroderma) is a disease charac-
terized by immune activation and inflammation that leads
to vasculopathy and fibrosis. It can affect the skin, blood
vessels, and internal organs. The internal organs most
commonly affected are kidney, gastrointestinal tract, and
lung. Over the past decade, the use of angiotensin-
converting enzyme inhibitors has greatly reduced the
burden of renal complications, making lung disease the
leading cause of morbidity and mortality in SSc patients [1].
The two principal manifestations of SSc lung disease are
pulmonary arterial hypertension (PAH) and interstitial lung
disease (ILD) [2].
PAH is a lethal disease characterized by elevated pulmo-
nary artery pressure that leads to dyspnea, heart failure, and
death. In the setting of SSc, the prevalence of PAH ranges
from 5% to 12% [3e5], and is a leading cause of death [6,7].
Historically, SSc-PAH had a median survival of 12 months [6].
In the modern treatment era, the median survival has
improved to 3e4.9 years [5,8,9]. Similarly, idiopathic pul-
monary arterial hypertension (IPAH) historically has a me-
dian survival of 2.8 years [10]. In the modern treatment era,
3-year survival has improved to 76%e85% [9,11,12]. The use
of PAH-specific therapies (endothelin receptor antagonists,
phosphodiesterase 5 inhibitors and prostaglandin analogues)
used alone or in combination, has resulted in improvements
in six-minute walk distance, functional class, cardiac he-
modynamics, quality of life and time to clinical worsening
[13]. Yet none of these treatments are curative.
ILD also portends a poor prognosis, with mean survival of
2e5 years from the time of diagnosis [14]. Estimated mor-
tality rates are 64.3 deaths per million men and 58.4 deaths
per million women [15]. Prognostic factors for survival in
SSc-PAH, SSc-ILD and IPAH include baseline mean pulmo-
nary artery pressure, sex, functional class and signs of right
heart failure [16].
Lung transplantation is performed to prolong survival and
to improve the quality of life for patients with end stage lung
disease [17]. Nearly three decades have passed since the
procedure was first introduced, and this extended experi-
ence has led to improvements in outcomes for lung trans-
plant recipients. Despite the recent increase in the number
of patients undergoing lung transplantation over the past
decade, patients with systemic autoimmune rheumatic dis-
ease, such as SSc, are often denied transplantation because
of concerns about the short- and long-term outcomes [18].
However, very little is known about the survival of SSc
patients, who undergo lung transplantation. The objectiveof this study was to evaluate survival of SSc patients’ post-
lung transplantation through a systematic review of the
literature. We secondarily evaluated SSc lung transplant
recipient characteristics such as age, sex and SSc lung dis-
ease type, and discussed post-lung transplantation survival
of non-SSc patients (idiopathic PAH, and ILD).
Methods
Data sources and searches
An investigator (IYK) and an information specialist from the
University Health Network library services independently
performed the literature search. Studies were identified
using Ovid MEDLINE (1986e2012), EMBASE (inception to
January 2012) Cochrane Central Registry of Controlled Trials
(inception to 2012) and CINAHL (inception to 2012). The
following keywords, alone or in combination, with mapping
of term to subject headingwere used in the database search:
“scleroderma”, “systemic sclerosis”, “lung trans-
plantation”, “pulmonary fibrosis”, and “pulmonary hyper-
tension”. No language, publication date or publication status
restrictions were imposed. The results of the 2 independent
searches were compared to ensure completeness.
Study selection
Titles and abstracts were screened to identify studies
reporting survival post-lung transplantation in SSc patients.
Studies were included if they reported 1) human SSc pa-
tients (classified as SSc using the American College of
Rheumatology classification criteria [19], or physician-
based diagnosis), 2) lung transplantation (single lung, dou-
ble lung or heart lung transplantation), and 3) reported
survival as an outcome. The primary outcome for this study
was death from all causes. Studies were ineligible if they
included 1) only individuals aged <16 years, 2) lung trans-
plantation for indications other than SSc-PAH or SSc-ILD, 3)
patients with another rheumatic disease (rheumatoid
arthritis, systemic lupus erythematosus, mixed connective
tissue disease), or 4) were animal studies. The reference
lists of selected articles were hand searched for relevant
publications.
Data abstraction
Two reviewers (IYK, AK) independently abstracted data
using standardized, pilot tested forms. The reviewers were
Figure 1 Flow diagram of systematic review.
Scleroderma and lung transplant 2083blinded to the names of authors, institutions and journals
when performing data abstraction. Data collection included
study design, age, sex, sample size, type of lung trans-
plantation, 6-month, 1-, 2- and 3-year survival data. Death
was defined as all-cause mortality. Survival data were taken
directly from the text, tables or Kaplan Meier figures. All
disagreements were resolved through consensus.
Reporting of this study is compliant with the PRISMA
statement [20].Results
Search results
Two hundred twenty-six citations were identified.
Screening of titles and abstracts resulted in the exclusion of
186 citations, leaving 40 citations for full review. DetailedTable 1 Demographic characteristics of systemic sclerosis patie
Reference N Mean age Sex female:male
Massad 2005 47 46 27:20
Schachna 2006 29 46.6 16:13
Shitrit 2009 7 52 5:2
Saggar 2010 15 53.2 4:11
Crespo 2011 67 49 NR
Sottile 2011 22 NR NR
Pakhale 2002 9 NR 5:4
PAH Pulmonary arterial hypertension, ILD Interstitial lung disease, SLT
transplant.review of these 40 citations identified 7 papers or abstracts
that reported post-lung transplant survival in SSc patients.
No randomized controlled trials were identified. Fig. 1.
SSc and lung transplant studies
Seven studies report approximately 186 SSc patients who
underwent lung transplantation (55 single lung, 50 double
lung, 2 heart-lung transplant, remaining not reported). Five
studies report outcomes in US centers, 1 study reports
outcomes in 1 center in Canada, and 1 study reports out-
comes in 1 center in Israel. There is some overlap in cohorts
between studies precluding the ability to identify unique
patients, unique events, and subsequently precluding
meta-analysis of the data. Study characteristics are sum-
marized in Table 1.
Shitrit et al. report 7 SSc patients (5 females and 2
males) who underwent lung transplantation at Rabin Med-
ical Centre, Beilinson Campus, Israel between January 1997
and September 2006. The median age of the patients was
52 years. All the patients had ILD, and were positive for
anti-Scl-70 antibodies. All patients underwent single-lung
transplantation (SLT). The median time to transplantation
from diagnosis of pulmonary disease was 23 months.
Following a median follow-up of 12 months, the survival of
patients with SSc (88%) was similar to non-scleroderma lung
transplantation (84%) at the same center.
Massad et al. report a retrospective, multicenter cohort
of 47 SSc patients who underwent lung transplantation at 23
U.S centers between 1987 and 2004, and were reported to
the United Network for Organ Sharing. Women constituted
57% of the patients and the mean age was 46 years. Twenty-
seven (57%) patients received single lung transplant, and
the remaining received double lung transplant. The Kaplan
Meier 1- and 3-year survival rates were 67.6% and 45.9%,
respectively. The survival estimates were not statistically
significant compared to 10,070 patients who underwent
transplant for other lung conditions during the same period
(75.5% and 58.8%, respectively, p Z 0.25).
Saggar et al. retrospectively evaluated lung transplant
recipients who underwent lung transplant between Januarynts who have undergone lung transplantation.
PAH (%) ILD (%) Type of lung transplant
NA NA 27 SLT
20 DLT
11 15 9 DLT
18 SLT
2 HLT
6 (84) 7 (100) 7 SLT
2 6 1 SLT
14 DLT
NR NR NR
NR 22 (100) NR
NR NR 7 DLT
2 SLT
Single lung transplant, DLT Double lung transplant, HLT Heart lung
2084 I.Y. Khan et al.1, 2003 and December 31, 2007 at the University of Cali-
fornia Los Angeles (UCLA), CA, USA. Inclusion criteria for
transplant listing included age 60 years, SSc diagnosis 5
years, and baseline six minute walk distance 100 m.
Exclusion criteria included symptomatic esophageal stric-
ture or upper gastrointestinal ulcer, esophageal atonia or
achalasia, or abnormal gastric emptying (<25% clearance at
90 min post ingestion) despite aggressive medical therapy.
A total of 243 lung transplants were performed during this
period, out of which 15 were for SSc and 38 were for IPF
patients. All lung transplants for SSc were double lung
transplants, except for one who underwent single lung
transplant. Apart from a younger SSc cohort (53.2 versus
58.8 years; p Z 0.02) the two groups were well matched.
During a median follow up of 632 days (SSc) and 788 days
(IPF), the post-lung transplant survival (78.6% versus 71.1%)
was no different [21].
Schachna et al. report a retrospective cohort of all pa-
tients who underwent lung transplantation between
December 1, 1989 and June 30, 2002 at the Johns Hopkins
Hospital and the University of Pittsburgh Medical Center. A
total of 689 lung transplantations were performed at the 2
centers during the study period. Survival following lung
transplantation was examined among 29 patients with SSc
as compared to 70 patients with ILD, and 38 patients with
IPAH. The primary outcome was all-cause mortality. Cu-
mulative survival at 6 months post-transplantation was 69%
in the SSc group, compared with 80% in the ILD group and
79% in the IPAH group. Over the following 18 months, there
was convergence in the survival rates such that cumulative
survival at 2-years was comparable at 64%, among all 3
groups [22].
Crespo et al. report a retrospective cohort study of pa-
tients who underwent lung transplant between July 1989
and December 2010 at the University of Pittsburgh Medical
Center. They compared 67 patients with SSc to 223 patients
controlled for era, age and disease (non-SSc). The average
age was 49 years. KaplaneMeier survival for SSc patients at
30 days, 1- and 5- years were 91%, 73% and 46%, compared
with non-SSc survival estimates of 95%, 86% and 52%.
Overall mortality for SSc patients was 11% compared to 13%
for non-SSc patients (time frame not specified) [23].
Pakhale et al. retrospectively reported the outcomes of
9 SSc patients from 415 patients who underwent lung
transplantation at the Toronto General Hospital, Toronto,
Canada between November 1983 and January 2001. Five
patients were females and four were males and their mean
age was 47 years. Seven received double lung trans-
plantation and two received single lung transplantation.
Survival at 30 days was 88.9%. The median survival time was
46 months (range 1e116 months) [24].
Sottile et al. retrospectively reported 22 SSc patients
who underwent lung transplantation at University of Cali-
fornia San Francisco, USA between 1998 and 2010. These
patients were matched by age and sex to 30 patients with
ILD and 11 patients with IPAH. The primary outcome was
post-transplant survival. In the SSc group, 6-month, 12-
month and 36- month survival was 85%, 79% and 68%
compared to 90%, 83% and 69% in the ILD group. In IPAH,
survival was 90% at 6-months, 12-months and 36-months.
Survival was not statistically different across all groups
(p Z 0.4) [25].Post-lung transplant survival
Survival data across studies are summarized in Table 2.
Causes of death included graft failure [18,26], infection
[18,26], cardiac events [18], hemorrhagic stroke [18], res-
piratory failure [18], malignancy, pulmonary hypertension
[18], complications of bronchiolitis obliterans syndrome
[21], scleroderma renal crisis [21], anesthetic complication
[21]. There were no reports of recurrence of SSc in the lung
allograft. The inclusion criteria for each study are sum-
marized in Table 3.Discussion
Lung transplantation is a potentially life-saving option for
SSc patients with end stage lung disease. Our systematic
review indicates that SSc post-lung transplant survival is
good. Some lung transplant programs have expressed
concern about the possibility of excess post-
transplantation mortality related to the extra-pulmonary
manifestations of SSc [21]. The results of this review
suggest that this is possibly not the case. Furthermore,
there has been a progressive improvement in survival
rates over time. Indeed, there has been a substantial
decrease in 30-day mortality for PAH patients post-lung
transplantation over the past 2 decades [28]. The SSc
patients have kept pace with the overall cohort of pa-
tients with time. The observed improvement in SSc post-
lung transplant survival is likely attributable to
increasing experience across centers resulting in im-
provements in perioperative and post-lung transplant care
over time. However, within the SSc group, there was
considerable variability in survival estimates (e.g. 67.6%e
93.4% survival at 1-year post-transplantation) [18,21]. The
study with the best survival outcomes had more stringent
recipient selection criteria [21]. It is likely that these
patients were highly selected, and thus had the best
survival outcomes, compared to the other studies.
Furthermore, the presented data suggests that there
possibly are no differences between groups, but is not
conclusive. Definitive conclusions cannot be drawn based
on these studies. Studies with larger samples or even more
studies, which can be included in a meta-analysis, are
needed to definitively answer this important question.
The comparability of SSc post-lung transplant survival in
relation to non-SSc (IPAH and ILD) lung transplant survival is
controversial. Two studies demonstrate comparable sur-
vival between SSc and non-SSc lung transplant recipients
[22,26], one study demonstrates better survival in among
non-SSc lung transplant recipients [18], and one study [21]
demonstrates better survival among the SSc lung transplant
recipients. The reasons for these discrepancies are unclear.
The first reason may relate to the processes of access to
lung transplantation. Very few studies have characterized
SSc patients referred for lung transplant assessment, those
deemed unsuitable for transplantation, those who refuse
lung transplantation, those considered too early to be lis-
ted, those who die before their assessment or die on the
transplant list. Waiting list mortality has been reported to
be highest among connective tissue disease (CTD) associ-
ated PAH patients [28]. SSc pre-transplant disease
Table 2 Survival post-lung transplantation in systemic sclerosis.
Reference N 30 day survival 6-month
survival
1-year survival 2-year survival 3-year survival
SSc Non-SSc SSc Non SSc SSc Non-SSc SSc Non-SSc SSc Non-SSc
Pakhale 2002 9 88.9% NA NR NA NR NA NR NA NR NA
Massad 2005 47 85% NR NR NR 67.6% 75.5% 58% 66.5% 45.9% 58.8%
Schachna 2006 29 69% 80% ILD
79% IPAH
69% 80% ILD
79% IPAH
59% 59% ILD
74% IPAH
52% 37% ILD
58% IPAH
NR NR
Shitrit 2009 7 NR NR NR NR 88% 84% NR NR 73% NR
Saggar 2010 15 NR NR NR NR 93.4% 86.9% 80% 71.1% NR NR
Crespo 2011 67 91% 95% NR NR 73% 86% NR NR NR NR
Sottile 2011 22 NR NR 85% 90% ILD
90% IPAH
79% 83% ILD
90% IPAH
NR NR 68% 69% ILD
90% IPAH
SSc Systemic sclerosis, Non-SSc Non systemic sclerosis, ILD Interstitial lung disease, IPAH Idiopathic pulmonary arterial hypertension, NA
Not applicable, NR Not reported.
Scleroderma and lung transplant 2085manifestations, disease severity, patient preferences and
socio-economic factors all may impact post-lung transplant
prognosis. As such, discrepancies could reflect how the
cohorts were matched or how potential confounders wereTable 3 Summary of inclusion criteria.
Saggar
General
Adherence to established guidelines U
Age 60 yrs.
SSc diagnosis 5 yrs.
Baseline 6MWT 100 m
(with oxygen
FVC NR
Gastrointestinal
Absence Severe gastroesophageal reflux NR
Oesophageal stricture U
Active UGI ulceration U
Oesophagealperistalsis U
Abnormal gastric emptying U
Chronic GI bleed U
Skin
Chest induration score
Absence Non-healing wounds NR
Open skin wounds NR
Severe sclerosis of chest wall NR
Rapidly progressive diffuse skin thickening U
Active digital ulcerations U
Active myositis U
Progressive myopathy U
Renal
Creatinine clearance >50 ml/min
Time between last renal crisis & active listing for LT Min of 5 yrs.
Cardiac
Absence Left heart failure U
CAD U
Overt right heart failure U
NR Not reported.
a Abstract.accounted for. The small sample sizes make control of
relevant prognostic factors problematic.
Second, the combined effect of SSc manifestations and
post-operative morbidity may also impact survival.Schachna Shitrit Massad Crespoa Phaklea Sottilea
U NR NR NR NR NR
NR NR NR NR NR NR
NR NR NR NR NR NR
)
NR NR NR NR NR NR
<55% NR NR NR NR NR
U NR U NR NR NR
NR NR NR NR NR NR
NR NR NR NR NR NR
NR NR NR NR NR NR
NR NR NR NR NR NR
NR NR NR NR NR NR
U NR NR NR NR NR
U NR U NR NR NR
U NR NR NR NR NR
NR NR NR NR NR NR
NR NR NR NR NR NR
NR NR NR NR NR NR
NR NR NR NR NR NR
>50 ml/min NR >50 ml/min NR NR NR
NR NR NR NR NR NR
NR NR NR NR NR NR
NR NR NR NR NR NR
NR NR NR NR NR NR
2086 I.Y. Khan et al.Gastroparesis (as measured by delayed gastric emptying on
nuclear gastric emptying studies) and gastroesophageal
reflux are common in lung transplant recipients, and are
associated with the development of bronchiolitis obliterans
syndrome (BOS) in the lung allograft [29,30]. The presence
and extent of gastroesophageal reflux may increase
concern for graft refection [27] SSc-ILD patients have more
reflux episodes and more reflux reaching the proximal
esophagus compared with SSc patients without ILD [31].
This could possibly also explain some of the variability in
results post transplant for SSc-ILD versus SSc-PAH. Other
SSc-related morbidity that should be considered includes
the occurrence of infection, gastrointestinal complications
(aspiration, reflux, need for feeding tube), and renal
complications including need for dialysis. An improved un-
derstanding of the occurrence, management and possible
prevention of these post-lung transplant co-morbidities will
likely improve lung allograft outcomes and survival.
A third reason for the discrepancies in survival estimates
between SSc and non-SSc lung transplant recipients may be
due to biased case-ascertainment (related to classification
versus diagnosis of SSc [19], or insufficient characterization
of the etiology of lung disease.) It may be that there are
survival differences across SSc-PAH, SSc-ILD, SSc with
combined PAH and ILD, IPAH and ILD. Mixing of these sub-
groups as ‘cases’ and ‘controls’ may bias the survival esti-
mates. Future investigators should report the criteria by
which each subgroup was classified, and outcomes for each
of the subgroups under study.
We have also found that very little is known about long-
term SSc post-lung transplant survival. The studies we have
identified only report short-term (30-day and 6-month), and
intermediate-term (1-, 2-, 3-year) survival. Long-term sur-
vival data are needed. It has been reported that long-term
post-lung transplant survival (10-year) in CTD-PAH is 69%,
and is better than IPAH post-lung transplant survival [28].
There were no reports of recurrence of SSc in the lung
allograft. It should be noted that simply not reported does
not preclude such a possibility. It might be difficult to
distinguish graft rejection from SSc, since both are char-
acterized by vascular damage, inflammation and fibrosis.
There are a few limitations to consider in our system-
atic review. The only recipient characteristics, which we
evaluated, were age, sex and the type of SSc lung disease.
We feel that there is a scope for future investigators to
evaluate further recipient characteristics such as disease
duration, time to lung transplant, type of SSc, other organ
system involvement, especially gastrointestinal tract. All
of the studies were retrospective observational studies;
hence there may be selection bias and the potential for
missing data in these studies. All of the studies had small
sample sizes, and were limited in longitudinal follow-up.
These limitations are not insurmountable. A more signifi-
cant issue is that the publications may contain overlapping
cohorts of the same patients [32]. For example, the study
reported by Massad et al. includes all US patients with an
identified diagnosis of SSc. It may be that some patients
are counted multiple times. As a result there is insufficient
scientific basis for combining these studies as a meta-
analysis. However, the descriptive systematic review is
worthwhile and interesting. Our study synthesizes the
current state of knowledge, and lays the groundwork forfuture research. We have found that there is a significant
gap in understanding the determinants of post-lung
transplantation survival in SSc patients. Review of the
United Network for Organ Sharing (UNOS) or the Interna-
tional Society for Heart and Lung Transplantation (ISHLT)
databases may further answer these questions. However,
these databases only contain information on transplanted
patients and not those with SSc that were referred for
transplant or refuse transplant. Future researchers need
to clearly delineate the access process for lung trans-
plantation in SSc patients: who gets referred for assess-
ment, who gets listed and finally who undergoes lung
transplantation [32]. Undoubtedly, the assessment process
can result in selection bias and impact post transplant
survival. Investigators should report clinically relevant
outcomes post-lung transplant in SSc such as the occur-
rence of acute rejection, infection, bronchiolitis obliter-
ans syndrome, renal dysfunction and dialysis,
gastroparesis, and need for tube feeding.
Gastroesophageal reflux and altered motility are com-
mon among patients with SSc and post-lung transplantation
population [29]. This is of potential clinical importance as
both gastroesophageal reflux and aspiration may be modi-
fiable. There is increasing consideration of early anti-reflux
measures [26,33e35] in these patients. The occurrence of
these co-morbidities will impact survival and the quality of
life post-transplantation.
In conclusion, there remains a small body of literature
on the topic of lung transplantation in patients with SSc.
This study reviews several articles and compares the results
of these papers. Based on these studies, the short-term and
intermediate-term survival post-lung transplantation are
similar to IPAH and ILD patients requiring lung
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